Aspirin and HDAC regulation of endothelial function and vascular tone

阿司匹林和 HDAC 对内皮功能和血管张力的调节

• 批准号: 8730359
• 负责人: Kaikobad J. Irani
• 金额: $ 10.44万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-02-04 至 2015-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8730359
• 关键词: Aspirin; HDAC; regulation; endothelial; function

DESCRIPTION (provided by applicant): Low-dose acetylsalicylic acid (aspirin) is widely used in the treatment and prevention of vascular disease. Aspirin prevents platelet activation and aggregation, but is also known to have platelet-independent vasoprotective effects. Aspirin promotes endothelium- dependent vasorelaxation but mechanisms by which it does so are not completely understood. The principal hypothesis of this application is that reversible acetylation of lysine residues in endothelial nitric oxide synthase (eNOS) by low-dose aspirin stimulates eNOS activity, and promotes endothelium-dependent vascular relaxation. The novelty of this application lies in 1) determining the role of lysine acetylation of eNOS by low-dose aspirin as a post-translational modification that promotes eNOS enzymatic activity and thereby endothelial NO production, and 2) exploring the role of the endogenous lysine deacetylase, histone deacetylase-3 (HDAC3), in reversing aspirin- stimulated lysine acetylation of eNOS and thereby antagonizing aspirin-induced endothelial NO production. The significance of this proposal lies in 1) identifying a novel molecular mechanism through which cardiovascular doses of aspirin may have vasoprotective effects, and 2) identifying a potentially exploitable endogenous mechanism that antagonizes the effect of aspirin on the vasculature. Although low-dose aspirin is effective in the prevention and treatment of cardiovascular disease, a significant proportion of patients on aspirin experience atherothrombotic events, underscoring the importance of further understanding how aspirin functions in the vasculature. This application, by looking at lysine acetylation of eNOS as a new mechanism for the effect of low-dose aspirin on endothelial function, and by identifying an endogenous antagonist to aspirin in the endothelium, may pave the way for future strategies that better harness the therapeutic potential of this widely used pharmaceutical.

描述（由申请人提供）：低剂量乙酰水杨酸（阿司匹林）广泛用于治疗和预防血管疾病。阿司匹林可防止血小板活化和聚集，但也已知具有血小板非依赖性血管保护作用。阿司匹林促进内皮依赖性血管舒张，但其机制尚不完全清楚.本申请的主要假设是低剂量阿司匹林对内皮型一氧化氮合酶（eNOS）中赖氨酸残基的可逆乙酰化刺激eNOS活性，并促进内皮依赖性血管舒张。本申请的新奇在于1）确定低剂量阿司匹林作为促进eNOS酶活性并由此促进内皮NO产生的翻译后修饰的eNOS的赖氨酸乙酰化的作用，和2）探索内源性赖氨酸脱乙酰酶，组蛋白脱乙酰酶-3（HDAC 3），逆转阿司匹林刺激的eNOS的赖氨酸乙酰化，从而拮抗阿司匹林诱导的内皮NO产生。该建议的意义在于：1）确定心血管剂量的阿司匹林可能具有血管保护作用的新分子机制，以及2）确定拮抗阿司匹林对血管系统作用的潜在可利用的内源性机制。虽然低剂量阿司匹林在预防和治疗心血管疾病方面是有效的，但服用阿司匹林的患者中有很大一部分经历了动脉粥样硬化血栓形成事件，这强调了进一步了解阿司匹林在血管系统中如何发挥作用的重要性。通过将eNOS的赖氨酸乙酰化作为低剂量阿司匹林对内皮功能影响的新机制，并通过确定内皮中阿司匹林的内源性拮抗剂，该应用可能为未来更好地利用这种广泛使用的药物的治疗潜力的策略铺平道路。